I-Mab announced the publication of abstract #388MO for the European Society of Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025), detailing positive data from a Phase 1b study of givastomig. The study evaluated givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers.
The data showed an objective response rate (ORR) of 71% (12/17) across all dose levels in the dose escalation part of the study. Notably, an ORR of 83% (10/12) was observed at the 8 and 12 mg/kg dose levels, which have been selected for the ongoing dose expansion study.
The study also reported a favorable safety profile, with low incidence of gastrointestinal and liver toxicities. Responses were observed to be rapid in onset and deepened over time, occurring in tumors with low levels of PD-L1 and/or Claudin 18.2 expression.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.